Genetic polymorphisms and thromoembolic risk in atrial fibrillation [1]

Journal of Thrombosis and Thrombolysis

Volumn 18, Issue 2, 2004, Pages 151-152

  Marín, Francisco ^a   Roldán, Vanessa ^b   Tello, Antonio ^a   Lip, Gregory Y H ^c  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b Hospital de San Vicente   (Spain)

^c CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5 LEIDEN; INTERLEUKIN 6; PROTHROMBIN;

AGE; AMINO ACID SUBSTITUTION; ARTERY EMBOLISM; CARDIOVASCULAR RISK; CROSS LINKING; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; LETTER; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STROKE; THROMBOEMBOLISM; THROMBOGENESIS;

ATRIAL FIBRILLATION; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS; THROMBOEMBOLISM;

EID: 16844384187     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-004-0211-y     Document Type: Letter

References (10)

1. Go AS, Reed GL, Hylek EM, et al. Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. J Thromb Thrombolys 2003;15:41-46.
2. Hatzinikolaou-Kotsakou E, Kartasis Z, Tziakas D, et al. Atrial fibrillation and hypercoagulability: Dependent on clinical factors or/ and on genetic alterations? J Thromb Thrombolys 2003;16:155-161.
3. Feinberg WM, Pearce LA, Hart RG, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation. Correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke 1999;30:2547-2553.
4. Pengo V, Filippi B, Biasiolo A, Pegoraro C, Naventa F, Iliceto S. Association of the G20210A mutation in the Factor II gene with systemic embolism in nonvalvular atrial fibrillation. Am J Cardiol 2002;90:545-546.
5. Poli D, Antonucci E, Cecchi E, et al. Thrombophilic mutations in high-risk atrial fibrillation patients: High prevalence of prothrombin gene G20210A polymorphism and lack of correlation with thromboembolism. Thromb Haemost 2003;90:1158-1162.
6. Carter AM, Catto AJ, Grant PF. Association of the α-Fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999;99:2423-2426.
7. Roldán V, Marín F, Blann AD, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003;24:1373-1380.
8. Lip GYH. The prothrombotic state in atrial fibrillation: The atrium, the endothelium,... and tissue factor? Thromb Res 2003;111:133-135.
9. Marín F, Corral J, Roldán V, et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004;37:699-704.
10. Ariëns RAS, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects crosslinked fibrin structure. Blood 2000;96:988-995.